Many CT antigen genes were upregulated in TP53-mutated BCs and encode the CT antigens that are potential targets for developing cancer vaccines, e.g., MAGEA, NY-ESO-1, and PRAME (Supplementary Figure S4B; Table S16). This evidence concerns the gene TP53 and cancer.